Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Efficacy endpoint met; however, overall experimental dosing regimen is not considered optimal to support further clinical development in this patient population

Conditions

Leukemia, Myeloid, Acute
Myelodysplastic Syndromes

Interventions

DRUG: CC-91633

Sponsor

Celgene